Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis

Inês RAPOSO1, Andreia BETTENCOURT2, Luiz LEITE3, Manuela SELORES1,4,5, Tiago TORRES1,4,5

ABSTRACT
Introduction: Ustekinumab is a monoclonal antibody directed against the p40 subunit common to both IL-12 and IL-23 cytokines. Although the evidence of ustekinumab efficacy and safety in clinical trials is extensively recognized, data on its use in clinical practice is limited. Our objective is to report on the real-life experience of two Portuguese dermatology departments with ustekinumab in patients with moderate to severe psoriasis, and to identify the clinical characteristics associated with a weaker clinical response.

Material and Methods: Clinical, demographic, and therapeutic response data was retrospectively collected in 116 patients with moderate to severe psoriasis treated with ustekinumab between November 2009 and December 2015.

Results: A PASI75 therapeutic response was observed in 67.2%, 85.3%, 89.6% and 88.7% of patients at weeks 4, 12, 24 and 52, respectively. Ustekinumab was discontinued in seven patients (three due to primary failure, three due to secondary treatment failure, and one due to adverse events). Neither cardiovascular events nor cases of reactivation of previous infections (tuberculosis, hepatitis B) were observed during follow-up. In nine patients methotrexate was used as adjuvant therapy, and fourteen patients required ustekinumab dosage optimization. No side effects were observed in the two latter groups. The therapeutic response was higher in patients naïve to biologic therapies as compared to non-naïve patients.

Discussion and Conclusion: A trend towards lower clinical response was observed in patients weighing between 90-100 kg, and dosage optimization in this group of patients may be of value prior to considering biologic switch.

Keywords: Biological Products/therapeutic use; Psoriasis/drug therapy; Ustekinumab/therapeutic use

INTRODUCTION

Ustekinumab is a monoclonal antibody targeting the p40 subunit common to the IL-12 and IL-23 cytokines, whose therapeutic efficacy and safety are well documented in clinical trial populations.2,3

Body weight affects clearance capacity and volume of distribution of numerous drugs.4 Specifically, in the case of ustekinumab, the patient’s weight exerts a pronounced influence on pharmacokinetics by altering the drug clearance and distribution volume.5 This is the rationale for the recommendation of different dosing regimens of ustekinumab in patients below and above a defined weight threshold (45 mg or 90 mg every 12 weeks in patients weighing < 100 kg and ≥ 100 kg, respectively).1,6

As compared with clinical trials, the real-life practice with ustekinumab showed that a proportion of patients is either unresponsive or loses efficacy with the aforementioned dosage regimen.5,6 This scenario often leads to ustekinumab dosage increase, interval adjustments, introduction of additional therapy or consideration of biologic switch.2,3


Autor correspondente: Tiago Torres. torres.tiago@outlook.com

Revista Científica da Ordem dos Médicos 214  www.actamedicaportuguesa.com
adjuvant therapy, or biologic switch. Additionally, previous experience in clinical trials and real-life practice showed that, in certain patient groups the loss of therapeutic response can be a transitory phenomenon, and the intensification of the drug regimen may allow the maintenance of the initial biologic, as such avoiding the ‘exhaustion’ of other therapeutic choices.

Analysis of data derived from real-life practice that would enable the identification of clinical characteristics associated with a weaker clinical response, would, in some patients, allow considering alternative dosing regimens rather than just switching biologics.

The objective of our study is to identify the clinical characteristics associated with a weaker clinical response in patients with psoriasis treated with ustekinumab.

**MATERIAL AND METHODS**

The real-life experience of two Portuguese dermatology departments with ustekinumab in the treatment of moderate to severe psoriasis is hereby presented through a retrospective observational patient cohort. Clinical data of 116 patients treated with ustekinumab in Centro Hospitalar do Porto (Porto) and Clínica Laser de Belém (Lisboa) between November 2009 and December 2015 were collected. Demographic data, history of psoriasis (age of onset, family history), presence of psoriatic arthritis (PsA), baseline Psoriasis Area Severity Index (PASI), along with previous therapies, comorbidities, serious adverse events (SAE), and therapeutic response were assessed.

**RESULTS**

**Cohort clinical and demographic characteristics**

A total of 116 patients with moderate-to-severe psoriasis (50 female and 66 male patients) treated with ustekinumab were retrospectively analysed. The mean age of onset of psoriasis in our cohort was 26 years (± 15.2, range 2 - 71), while mean disease duration was 21.8 years (± 12.8, range 4 - 62). Twenty-four (20.7%) patients had a diagnosis of PsA in our cohort. Regarding disease severity, the mean baseline PASI was 13.2 (± 5.1, range 8 - 27.6). Mean weight of our cohort of patients was 78.3 kg (± 17.2, range 46 - 118), and mean body mass index (BMI) was 27.3 (± 5.1, range 17.9 - 46.9).

The prevalence of cardiovascular risk factors was analysed: hypertension was present in 30.2% patients, dyslipidaemia in 30.2%, and diabetes in 11.2% patients. Obesity (BMI > 30) and overweight (BMI 25 - 30) were identified in 23.3% and 39.7% of our patient cohort, respectively. Re-
Regarding smoking status, 32.8% of patients were current smokers, while 21.6% had smoked in the past. Pre-treatment infectious screening identified 52 cases of latent tuberculosis and two patients with serologic tests compatible with past hepatitis B viral infection (HBcAb positive; HBsAg negative; HBV DNA negative).

Regarding previous therapies – phototherapy, cyclosporine, methotrexate and acitretin were previously used in 37.9%, 27.6%, 23.3% and 25% patients, respectively. The majority of our group of patients (93 patients; 80.2%), was naïve to biologic treatments. Among the 23 patients (19.8%) who had prior biologic experience, there was a mean washout period of 5.5 weeks. Infliximab, adalimumab and etanercept were previously used in 21.7%, 30.4% and 47.8% of patients, respectively. Three patients experienced more than one previous biologic.

**Therapeutic response analysis**

The therapeutic response (defined as PASI75 or more) at week 4, 12, 24, 52 was recorded, as was the total treatment duration. Primary endpoint analysis was made at week 12, 24 and 52. Missing data from the main cohort were handled using intention-to-treat non-responder imputation (ITT-NRI) analysis, using SPSS.

Regarding response to treatment, PASI75 response was achieved by 67.2% (78/116), 85.3% (99/116), 89.6% (104/116) and 88.7% (103/116) at week 4, 12, 24 and 52, respectively. In our patient cohort, the maximum total group follow-up was week 60, at which response rate remained sustained (102/116; 87.9%).

Naïve patients achieved superior clinical response as compared to non-naïve patients, and that was statistically significant at week 24 (p = 0.045) (Fig. 1). This finding goes in line with observations reported by other groups.8,16 In fact, the clinical response to a drug switch in patients with biologic experience is generally lower than in naïve patients, not only for ustekinumab, but also for other therapeutic classes.15

Regarding treatment interruption, ustekinumab was discontinued in seven patients [3 due to primary failure, 3 due to secondary treatment failure, and one due to adverse event (facial palsy)].

Considering patients that have escaped standard treatment, in 13 dosing intervals were temporarily reduced (8/8 weeks) due to loss of efficacy, and one patient required a dose escalation due to weight gain and worsening of the disease.

Concerning adjuvant therapy, methotrexate was used in one patient at the beginning of treatment (concomitant diagnosis of PsA), and as add-on therapy in eight patients due to loss of clinical response. Five out of eight of these patients later regained PASI75 response. The use of methotrexate is reported to help maintain clinical response, not only due to the drug’s adjuvant immunosuppressive action but also owing to a collateral effect of inhibition of production of anti-drug antibodies.11 No adverse events were reported in this group of patients, but further long-term studies are needed to establish the long-term effects of this immunomodulatory association. Until then, a case-to-case scenario evaluation needs to be assessed for every individual patient.

Considering the treatment response according to the patients’ weight (Fig. 2), a tendency to inferior clinical response was observed in patients weighing 90 - 100 kg. When patients under the standard dose of ustekinumab were analysed, this difference was statistically significant at week 24 (p = 0.035). These observations are in accordance with previous reports, which seem to point to a probable need of up-dosing in these patients, as the proximity to the ‘weight-adjustment’ threshold makes clinical response to 45 mg of ustekinumab less efficacious.10

Seventy-four patients had a follow-up duration of at least 120 weeks. When analysing a cohort subset that

---

Figure 2 – Number of patients achieving PASI75 response (%), stratified by weight categories, < 90 kg, 90 – 100 kg and ≥ 100 kg. (A): total cohort of patients (total n: 116); (B): patients under standard dosage of ustekinumab (total n: 102).

*: p = 0.035
includes these long-term follow up patients along with pa-
tients that discontinued treatment during our study period, 
the observed PASI75 response was 80.7% (63/78), 84.6% 
(66/78), 87.2% (68/78), and 94.9% (74/78) at week 12, 24, 
52 and 120. These long-term follow-up PASI75 values un-
derline{line} that the initial response to treatment represents the 
primary predictor of ultimate therapeutic success in a given 
patient, and that the continuation of treatment makes failure 
less probable (excluding factors such as development of 
side effects or weight increases that lessen drug efficacy).

As far as adverse events, one patient developed facial pal-
y during treatment (week 180), and even though this event 
was not proven to be associated to the drug, the possible 
relation led to ustekinumab suspension. No major adverse 
cardiovascular events (MACE) were reported dur-
ing the treatment period. Regarding screening of infectious 
diseases, adequate prophylaxis was implemented and no 
reactivations were detected during follow-up.

**DISCUSSION AND CONCLUSION**

Our experience with the long-term use of ustekinumab in 
a heterogeneous group of real-life patients demonstrated an 
excellent safety profile and absence of major adverse 
events. Despite a high prevalence of cardiometabolic and 
fectious comorbidities in our cohort, it is important to note 
the absence of related SAEs during follow-up.

Upon secondary failure during treatment of moderate 
to severe psoriasis with biologics, there is uncertainty con-
cerning the decision to either switch to another agent or to 
intensify the primary biological (by altering drug dose or the 
frequency of administration).6 Decision-making has to take 
into account not only the expected therapeutic response, 
but also the economic impact of these options. On the one 
hand, the cost of introducing a new biological will require 
taking into consideration not only the new induction phase 
but also the costs that are inherent to additional medical vis-
its and diagnostic tests.15 On the other hand, the cost of the 
therapy intensification will depend on the amount and dura-
tion of the latter.15 The suspension and initiation of biologic 
therapy should be judicious insofar as patients experienced 
with prior biologics appear to have suboptimal therapeutic 
response rates, as observed in our patient group.

We report a sustained long-term PASI75 response and 
treatment persistence in the majority of our group of pa-
ten. An inferior therapeutic response was observed in 
non-naïve patients and patients in the 90 - 100 kg weight 
interval, which goes in line with previous reports. This find-
ning seemingly indicates that the proximity to the upper limit 
of the weight threshold is associated with a significant re-
duction of therapeutic response rates. The TRANSIT study 
demonstrated the benefit of dose escalation from 45 to 90 
mg in patients weighting < 100 kg who did not reach PASI75 
at week 28.17 Despite the low number of patients in each of 
the weight categories in our cohort of patients, it seems that 
the dosage-adjustment threshold may have been set too 
high. The significance of weight in treatment efficacy em-
phasizes the importance of regular weight measurements in 
medical appointments in these patients, as previously sug-
gested.10 The usefulness in clinical practice of the aware-
ness and recognition of this group of patients may be note-
worthy for implementation of weight reduction plans (dietary 
change, exercise prescription) along with both temporary 
dose escalation and interval shortening, prior to taking into 
consideration drug switching due to treatment failure.

Weight loss is recommended in all psoriatic patients 
who are overweight or obese.17 This measure is essential 
not only to reduce cardiovascular risk burden, but also to 
optimize clinical response to several therapies.19

In conclusion, ustekinumab is an effective and safe ther-
apeutic agent in patients with moderate to severe psoriasis, 
and our experience has furthermore shown the ability of re-
capturing clinical response via temporary dose adjustments 
as well as a safe drug interaction profile with adjuvant ther-
apy such as methotrexate.

**PROTECTION OF HUMANS AND ANIMALS**

The authors declare that the procedures were followed 
according to the regulations established by the Clinical Re-
search and Ethics Committee and to the Helsinki Declara-
tion of the World Medical Association.

**DATA CONFIDENTIALITY**

The authors declare having followed the protocols in 
use at their working center regarding patients’ data publica-
tion. Patient consent obtained.

**CONFLICTS OF INTEREST**

Tiago Torres has participated as medical consultant/ 
speaker/advisory board member for Janssen, Pfizer, Ab-
vie, MSD, Novartis, Lilly, Celgene, Boehringer Ingelheim. 
The other authors report no conflict of interest.

**FUNDING SOURCES:**

This research received no specific grant from any fund-
ing agency in the public, commercial, or not-for-profit sec-
tors.

**REFERENCES**


